diphtheria toxoid + tetanus toxoid + hepatitis B (recombinant) vaccine + Haemophilus influenzae type b vaccine

This drug is a quadrivalent combination vaccine designed for the active immunization of infants and children against diphtheria, tetanus, hepatitis B, and invasive diseases caused by *Haemophilus influenzae* type b (Hib). It consists of diphtheria and tetanus toxoids, recombinant hepatitis B surface antigen (HBsAg), and the purified capsular polysaccharide of Hib conjugated to a carrier protein (typically tetanus toxoid). A distinguishing feature of this specific formulation is its 'low thiomersal' content (typically 0.005% or 0.025 mg per 0.5 mL dose), which serves as a preservative in multi-dose vials while minimizing mercury exposure. This quadrivalent combination is often utilized in clinical settings where the pertussis component of standard pentavalent vaccines is contraindicated. The vaccine works by inducing the production of specific IgG antibodies against the respective toxins and surface antigens, providing long-term immunological memory and protection against infection.

Other names

diphtheria toxoid + tetanus toxoid + hepatitis B (recombinant) vaccine (low thiomersal) + Haemophilus influenzae type b vaccineDT-HepB-Hib vaccinequadrivalent DT-HepB-Hib vaccine